Skip to content

Clinical trials

Anterior Cruciate Ligament Injuries trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Anterior Cruciate Ligament Injuries Clear all

616 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20022
20032
20044
20054
20065
20075
20084
20095
20106
20118
20126
201310
201412
201523
201629
201732
201841
201938
202037
202173
202265
202345
202461
202550
202646

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed248
Unknown status143
Recruiting97
Not yet recruiting41
Active, not recruiting29
Terminated28
Enrolling by invitation16
Withdrawn14

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking University Third Hospital32
University of Michigan11
Chinese University of Hong Kong10
GCS Ramsay Santé pour l'Enseignement et la Recherche9
Assiut University7
Chang Gung Memorial Hospital7
Hospital for Special Surgery, New York7
Indonesia University7
University Hospital, Caen7
University of North Carolina, Chapel Hill7

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Anterior Cruciate Ligament Injuries616
Knee Injuries52
Postoperative Pain17
Osteoarthritis, Knee15
Athletic Injuries14
Osteoarthritis14
Wounds and Injuries12
Muscle Weakness10
Rupture8
Kinesiophobia6

Trials

Showing 76 to 100 of 616. Each trial links to its page on Pharma Observatory.

516 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.